Also known as ZP8396
Zealand Pharma and Roche’s once-weekly amylin analog — positioned as a better-tolerated alternative to GLP-1. Phase 2 ZUPREME-1 reported up to 10.7% weight loss at 42 weeks.
Research refreshed
Petrelintide is an investigational long-acting amylin analog designed for once-weekly dosing and — unlike native amylin — chemical and physical stability at neutral pH, which permits co-formulation with other peptides. Developed by Zealand Pharma and partnered with Roche in 2025, it is aimed at weight loss with fewer gastrointestinal side effects than the GLP-1 class. The Phase 2 ZUPREME-1 trial reported up to 10.7% mean weight reduction at 42 weeks versus 1.7% on placebo, with discontinuation for adverse events no higher than placebo. It is not approved.
Amylin is the satiety hormone co-secreted with insulin. The native peptide is short-lived and aggregates into amyloid fibrils, which is why the first amylin drug, pramlintide, needs injections with every meal. Petrelintide is a second-generation answer: an acylated analog with a half-life of about ten days and no tendency to fibrillate at neutral pH — the property that lets it be mixed in one solution with a GLP-1 or GIP/GLP-1 agonist.
Zealand Pharma’s thesis is tolerability. If amylin agonism can deliver meaningful weight loss with less nausea and vomiting than the incretins, it has a role both as a standalone option for people who cannot stay on GLP-1 therapy and as a combination partner. In March 2025 Roche entered a co-development and co-commercialization agreement for the molecule, including combination with its own GIP/GLP-1 agonist CT-388.
The Phase 2 ZUPREME-1 trial, reported in 2026, enrolled about 490 adults with obesity or overweight and met its primary endpoint at week 28; at week 42 mean weight reduction reached 10.7% on the top dose versus 1.7% on placebo. Nausea was reported by 19.6% of participants on petrelintide versus 6.2% on placebo, and discontinuation for adverse events was 4.8% versus 4.9%. The weight effect is smaller than the leading incretins — or than Lilly’s amylin agonist eloralintide in its own Phase 2 — so the program’s case rests on the tolerability profile. Phase 3 monotherapy trials were slated to start in the second half of 2026.
Agonism at amylin and calcitonin receptors → hindbrain satiety signaling and slowed gastric emptying. A pathway distinct from GLP-1, studied for restoring leptin sensitivity and reducing food intake through increased fullness rather than nausea.
Behind every vial of Petrelintide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Petrelintide, specifically, is brought into being.
On paper, Petrelintide is C185H305N49O61 — about 4,192 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Petrelintide is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later. It also carries fatty-acid acylation, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Petrelintide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Petrelintide proves itself: identity confirmed by mass spectrometry against its ~4,192 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Petrelintide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Petrelintide to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Petrelintide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Petrelintide (ZP8396) is an investigational once-weekly amylin analog from Zealand Pharma, co-developed with Roche, studied for weight management as a monotherapy and in combination with incretin agonists.
It works through amylin and calcitonin receptors rather than the GLP-1 receptor. The weight loss reported so far is smaller than semaglutide or tirzepatide, but Phase 2 discontinuation for adverse events matched placebo — tolerability is the intended advantage.
All three are long-acting amylin-pathway agonists. Cagrilintide (Novo Nordisk) is the amylin half of CagriSema; eloralintide (Eli Lilly) reported larger Phase 2 weight loss; petrelintide (Zealand/Roche) emphasizes tolerability and co-formulation. They have not been compared head-to-head.
In the Phase 2 ZUPREME-1 trial, up to 10.7% mean weight reduction at 42 weeks versus 1.7% on placebo. Population means from a Phase 2 trial, not individual predictions.
No — it is investigational and has not completed Phase 3. This page is a research reference, not medical advice.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.